

IN THE CLAIMS

---

Claims 1-46 (Cancelled)

47(New). A method to treat a living body suffering from a disease selected from the group consisting of asthma, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory disease, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody and does not completely contain the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

48(New). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody and does not completely contain the amino acid sequences of the constant regions of said

non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

49(New). A method to treat a living body suffering from a disease selected from the group consisting of asthma, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory disease, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody and does not completely contain the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, and wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

50(New). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of

interleukin-18, which peptide comprises a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody and does not completely contain the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, and wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

---